While the clinical data for CB2 mediated anti-inflammatory response in lung inflammation is limited, several animal studies and preclinical data suggest that CB2 mediated effects in inflammatory processes are applicable for multiple etiologies of ARDS including COVID-19 and bacterial pneumonia. This evidence concerns the gene CNR2 and COVID-19.